Trevi Therapeutics, Inc. (TRVI) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Trevi Therapeutics, Inc.'s filing signal turned positive.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is an extended-release oral formulation of nalbuphine, which targets opioid receptors involved in the cough reflex. The company has announced positive topline results from its Phase 2b CORAL trial for IPF-related chronic cough and its Phase 2a RIVER trial for RCC. Trevi plans to initiate two pivotal Phase 3 clinical trials for IPF-related chronic cough in the second quarter of 2026 and a Phase 2b trial for RCC in the second quarter of 2026.

The company has not generated any revenue from product sales and expects to finance its operations through public or private equity offerings, debt financings, collaborations, and licensing arrangements until it can generate significant revenue from Haduvio, if approved.